In particular, the present invention is concerned with compounds of the general formula (I)
wherein X, Y and R
1
to R
10
are as described herein. The compounds are V1a receptor antagonists. The invention also relates to the manufacture of compounds of formula I, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases.
Substituted 1-benzazepines and derivatives thereof
申请人:Tomazic Alenka
公开号:US20050234041A1
公开(公告)日:2005-10-20
This invention relates to substituted 1-benzazepines and derivatives thereof useful as anti-infective agents, to compositions, including pharmaceutical compositions, comprising such compounds, to processes for making these compounds and to methods of using these compounds for killing bacteria and other microorganisms or inhibiting bacterial and other microorganism growth.
The invention relates to a novel group of compounds of Formula (I) or salts thereof:
wherein Y, Z
1
, Z
2
, R
1
, R
4
, R
5
and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
A method for continously extracting water soluble impurities from particulate arylene sulfide polymers in which a slurry of water and polymer containing from about 3 to about 30 percent by weight polymer is raised to a temperature in the range of about 250°F to about 420°F by continuous transfer of slurry in indirect contact with hot heat exchange medium followed by continuous separation of polymer from the water. In a preferred embodiment, the slurry is cooled before separation of polymer from the water and a closed cycle of heat exchange medium is used at least partially to heat and at least partially to cool the slurry during the process.
Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
申请人:ASTEX THERAPEUTICS LIMITED
公开号:US10544132B2
公开(公告)日:2020-01-28
The invention provides a compound of formula (I):
or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims.
Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.